DENVER, Colo. (247marketnews.com) -- Vaxcyte (NASDAQ:PCVX) delivered the kind of pivotal clinical readout that can fundamentally reshape a biotech investment story: its 31-valent pneumococcal vaccine candidate, VAX-31, met all prespecified primary endpoints in the pivotal OPUS-1 Phase 3 trial.
The headline result is particularly significant because VAX-31 was tested head-to-head against Prevnar 20 (PCV20) and Capvaxive (PCV21), two important existing adult pneumococcal vaccines. Among adults 50 and older, all 28 VAX-31 serotypes shared with one or both comparators met the company's stringent noninferiority threshold, while the three serotypes unique to VAX-31 plus cross-reactive serotype 20B met the prespecified superiority criterion.
VAX-31 did not appear to trade breadth for immune response. The company reported that the vaccine met noninferiority across all 321 serotype comparisons in its primary immunobridging analysis of adults 18-49 versus adults 50-64. Safety was also described as similar to PCV20 and PCV21, with no vaccine-related serious adverse events reported and no study discontinuations due to adverse events.
“We believe these positive OPUS-1 results provide clinical validation of our site-specific, carrier-sparing platform’s potential to deliver broader-spectrum pneumococcal vaccines while maintaining the magnitude of immune responses,” said Grant Pickering, Vaxcyte’s CEO and co-founder.
That broader coverage is the commercial argument. Vaxcyte says VAX-31 is designed to cover approximately 95% of invasive pneumococcal disease and 88% of pneumococcal pneumonia in U.S. adults aged 50 and older, potentially expanding coverage materially versus today's adult PCVs. The company estimates incremental coverage of 13%-36% for invasive disease and 19%-31% for pneumococcal pneumonia.
The catalyst calendar is now getting even more interesting. Vaxcyte expects results from OPUS-2 and OPUS-3 in the first half of 2027, followed by a planned Biologics License Application submission in the first half of 2028. The company is also advancing VAX-31 in infants, with Phase 2 data expected by the end of the first half of 2027.
Behind the clinical story is an increasingly well-capitalized company. Vaxcyte reported approximately $2.51 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial financial runway as it advances VAX-31 toward potential commercialization.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.